30th Jul 2020 17:56
Hutchison China MediTech Ltd - Hong Kong-based biopharmaceutical company - For first six months of 2020, pretax loss widened to USD76.6 million from USD68.3 million the year before, as overall expenses rose to USD184.9 million through increased administrative and R&D costs. This was despite revenue growing to USD106.8 million from USD102.2 million, driven by the Prescription Drugs business growing on the commercial sale of Elunate, as well as increased sales from Hutchison Sinopharm.
Current stock price: 407.00 pence
Year-to-date change: up 7.1%
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed